Ardelyx (ARDX) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 02/19/26
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 02/19/26
Insights Into Ardelyx (ARDX) Q4: Wall Street Projections for Key MetricsZacks Investment Research • 02/17/26
Ardelyx (ARDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/12/26
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026GlobeNewsWire • 02/05/26
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELAGlobeNewsWire • 01/28/26
Strength Seen in Ardelyx (ARDX): Can Its 15.0% Jump Turn into More Strength?Zacks Investment Research • 01/21/26
Wall Street Analysts See a 92.12% Upside in Ardelyx (ARDX): Can the Stock Really Move This High?Zacks Investment Research • 01/06/26
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney WeekGlobeNewsWire • 11/07/25
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor ConferenceGlobeNewsWire • 11/04/25
Ardelyx (ARDX) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 10/30/25
Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 10/30/25
Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual MeetingGlobeNewsWire • 10/28/25
Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney WeekGlobeNewsWire • 10/21/25